These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29095297)

  • 61. A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.
    Wang J; Zhao J; Fei X; Yin Y; Cheng H; Zhang W; Gu J; Yang F; Yang Y; Xue S; Tian Z; He J; Zhang S; Wang X
    Medicine (Baltimore); 2018 Apr; 97(17):e0228. PubMed ID: 29702970
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease.
    Großekatthöfer M; Güclü ED; Lawitschka A; Matthes-Martin S; Mann G; Minkov M; Peters C; Seidel MG
    Ann Hematol; 2013 Aug; 92(8):1121-8. PubMed ID: 23604429
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Outcome of allogeneic hematopoietic stem cell transplantation from HLA-matched sibling donor for 41 cases of severe aplastic anemia].
    Chen X; Wei JL; Huang Y; He Y; Yang DL; Jiang EL; Ma QL; Zhou LK; Lin XT; Shen YY; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):610-4. PubMed ID: 23134851
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin.
    Khoury H; Kashyap A; Adkins DR; Brown RA; Miller G; Vij R; Westervelt P; Trinkaus K; Goodnough LT; Hayashi RJ; Parker P; Forman SJ; DiPersio JF
    Bone Marrow Transplant; 2001 May; 27(10):1059-64. PubMed ID: 11438821
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Early blood stream infection following allogeneic hematopoietic stem cell transplantation is a risk factor for acute grade III-IV GVHD in children and adolescents.
    Sano H; Hilinski JA; Qayed M; Applegate K; Newton JG; Watkins B; Chiang KY; Horan J
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28921804
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Basiliximab as Treatment for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients after Haploidentical Hematopoietic Stem Cell Transplantation.
    Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
    Biol Blood Marrow Transplant; 2020 Feb; 26(2):351-357. PubMed ID: 31704470
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Analysis of risk factors for the development of acute graft-versus-host disease in 151 cases of allo-hematopoietic stem cell transplantation].
    Chen Y; Lu DP; Liu KY; Dong LJ; Ren HY; Huang XJ; Chen H; Liu DH; Jiang Q; Chen YH; Xu LP; Zhang YC; Lu J; Gao ZY
    Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):74-7. PubMed ID: 15921621
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Anti-CD25 monoclonal antibody with antithymocytic globulin for steroid-resistant severe acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation].
    Ye CX; Sun J; Liu QF; Qu H; Xu D; Zhang Y; Meng FY
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Dec; 28(12):2224-6. PubMed ID: 19114364
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study.
    Liu SN; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ; Mo XD
    Am J Hematol; 2020 Aug; 95(8):927-936. PubMed ID: 32311156
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.
    Khandelwal P; Lawrence J; Filipovich AH; Davies SM; Bleesing JJ; Jordan MB; Mehta P; Jodele S; Grimley MS; Kumar A; Myers K; Marsh RA
    Pediatr Transplant; 2014 Feb; 18(1):94-102. PubMed ID: 24384050
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
    Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
    Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies.
    Bay JO; Dhédin N; Goerner M; Vannier JP; Marie-Cardine A; Stamatoullas A; Jouet JP; Yakoub-Agha I; Tabrizi R; Faucher C; Diez-Martin JL; Nunez G; Parody R; Milpied N; Espérou H; Garban F; Galambrun C; Kwiatkovski F; Darlavoix I; Zinaï A; Fischer A; Michallet M; Vernant JP
    Transplantation; 2005 Sep; 80(6):782-8. PubMed ID: 16210965
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation.
    Inagaki J; Kodama Y; Fukano R; Noguchi M; Okamura J
    Pediatr Transplant; 2015 Sep; 19(6):652-8. PubMed ID: 26103520
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
    Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
    Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Chen X; Wang C; Yin J; Xu J; Wei J; Zhang Y
    PLoS One; 2015; 10(8):e0136991. PubMed ID: 26323092
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors.
    Wakamatsu M; Terakura S; Ohashi K; Fukuda T; Ozawa Y; Kanamori H; Sawa M; Uchida N; Ota S; Matsushita A; Kanda Y; Nakamae H; Ichinohe T; Kato K; Murata M; Atsuta Y; Teshima T;
    Blood Adv; 2019 Jan; 3(2):105-115. PubMed ID: 30626574
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation.
    Kwon M; Bailén R; Pascual-Cascón MJ; Gallardo-Morillo AI; García Sola A; Balsalobre P; Solán L; Dorado N; Muñoz C; Serrano D; Martínez-Laperche C; Buño I; Anguita J; Díez-Martin JL
    Blood Adv; 2019 Nov; 3(21):3351-3359. PubMed ID: 31698447
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Risk Factors for Graft-Versus-Host Disease After Transplantation of Hematopoietic Stem Cells from Unrelated Donors in the China Marrow Donor Program.
    Yang F; Lu D; Hu Y; Huang X; Huang H; Chen J; Wu D; Wang J; Wang C; Han M; Chen H
    Ann Transplant; 2017 Jun; 22():384-401. PubMed ID: 28652564
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Acute Graft-Versus-Host Disease: A Brief Review.
    Aladağ E; Kelkitli E; Göker H
    Turk J Haematol; 2020 Feb; 37(1):1-4. PubMed ID: 31475512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.